Latest Breaking News On - Andrea nye - Page 1 : vimarsana.com

Xylyx Bio announces exclusive license agreement with Vanderbilt University for donor organ rehabilitation asset

Toril Moi · I came with a sword: Simone Weil's Way · LRB 1 July 2021

Xylyx Bio and Alec Batis partner to launch Sweet Chemistry, a groundbreaking line of evidence-based regenerative skincare products

/PRNewswire/ -- Xylyx Bio, a regenerative medicine company, and Alec Batis, a renowned product innovator and research chemist, today announced a strategic...

Are you Woke?

Do you have any sexist, racist, xenophobic, homophobic or fat-shaming thoughts?

Xylyx Bio launches new website to showcase growing portfolio of regenerative biotechnologies

/PRNewswire/ -- Xylyx Bio, a New York-based regenerative medicine company leading the development of advanced biomaterials and biosystems, is proud to announce...

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

/PRNewswire/ -- A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for...

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

VIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare

VIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare

Xylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

Share this article NEW YORK and GRENOBLE, France, Feb. 2, 2021 /PRNewswire/ --  New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology. Cell&Soft Logo Existing in vitro models lack physiological relevance, yielding misleading and non-translatable results that slow essential progress needed to develop effective drugs capable of preventing thousands of cancer deaths each year.